Sino-Singapore Jingwei, November 30. On November 30, the three major indexes collectively opened higher.
The Shanghai Composite Index rose 0.23% to 3570.75 points, the Shenzhen Component Index rose 0.30% to 14,854.52 points, and the ChiNext Index rose 0.48% to 3,520.29 points. The PVDF concept, the titanium dioxide concept, and the NFT concept led the two markets. Artemisinin, biological products, precious metals and other sectors were among the top decliners.
The ratio of all trading stocks in Shanghai and Shenzhen stocks was 2619:1088. There were 13 daily daily limits and 1 daily limit.
As of November 29, the margin of margin trading in Shanghai and Shenzhen stocks was 1.85 trillion yuan.
The balance of financing on the day was 1.72 trillion yuan, an increase of 2.727 billion yuan from the previous trading day; the balance of securities lending that day was 130.658 billion yuan, a decrease of 832 million yuan from the previous trading day.
In terms of individual stocks, the daily limit shares during the call auction period are as follows: Sony Financial (10.01%), Zhongrui (10.06%), Jihong (10.01%), Changlu (10.06%), and Huasu (9.94%).
Hua'an Securities said that the Omi Keron mutant strain is coming, and it pays attention to the impact of commodities to repair the stock index: actively participate in the new year's market.
The economic downturn in December may stabilize the weakness, and the profitability of listed companies is expected to achieve a "soft landing". December is a relatively good time point for the layout. The industry configuration level will continue to shift to the growth style while maintaining a balanced configuration.
Yuekai Securities believes that, in the face of the impact of Omi Keron, the new crown vaccine and special medicine sectors whose valuations have returned to a reasonable range are worthy of focus.
It is recommended to pay attention to the leading companies in the new crown vaccine, the leading companies in the in-depth deployment of small molecule drugs, and the leading companies in the research and development of neutralizing antibodies.
(Zhongxin Jingwei APP)
(The opinions in the article are for reference only and do not constitute investment advice. Investment is risky, and you need to be cautious when entering the market.)